140 related articles for article (PubMed ID: 14562126)
1. Increased serum levels of interleukin-9 correlate to negative prognostic factors in Hodgkin's lymphoma.
Fischer M; Bijman M; Molin D; Cormont F; Uyttenhove C; van Snick J; Sundström C; Enblad G; Nilsson G
Leukemia; 2003 Dec; 17(12):2513-6. PubMed ID: 14562126
[TBL] [Abstract][Full Text] [Related]
2. Serum interleukin 6 levels are elevated in lymphoma patients and correlate with survival in advanced Hodgkin's disease and with B symptoms.
Kurzrock R; Redman J; Cabanillas F; Jones D; Rothberg J; Talpaz M
Cancer Res; 1993 May; 53(9):2118-22. PubMed ID: 8481913
[TBL] [Abstract][Full Text] [Related]
3. Serum soluble interleukin-2 receptor, beta2-microglobulin, lactate dehydrogenase and erythrocyte sedimentation rate in children with Hodgkin's lymphoma.
Bien E; Balcerska A
Scand J Immunol; 2009 Nov; 70(5):490-500. PubMed ID: 19874554
[TBL] [Abstract][Full Text] [Related]
4. Serum levels of cytokines and prevalence of autoantibodies in lymphoma patients and their prognostic value.
Uskudar Teke H; Gulbas Z; Bal C
J BUON; 2014; 19(1):191-7. PubMed ID: 24659663
[TBL] [Abstract][Full Text] [Related]
5. Serum level of intercellular adhesion molecule-1 in children with malignant lymphoma.
Abdelrazik N; Fouda M; Zaghloul MH; Abbas D
Med Princ Pract; 2008; 17(3):233-8. PubMed ID: 18408393
[TBL] [Abstract][Full Text] [Related]
6. Clinical relevance of soluble HLA-I and beta2-microglobulin levels in non-Hodgkin's lymphoma and Hodgkin's disease.
Albitar M; Vose JM; Johnson MM; Do KA; Day A; Jilani I; Kantarjian H; Keating M; O'Brien SM; Verstovsek S; Armitage JO; Giles FJ
Leuk Res; 2007 Feb; 31(2):139-45. PubMed ID: 16545870
[TBL] [Abstract][Full Text] [Related]
7. Real-time polymerase chain reaction determination of cytokine mRNA expression profiles in Hodgkin's lymphoma.
Malec M; Söderqvist M; Sirsjö A; MacNamara B; Lewin N; Sjöberg J; Björkholm M; Porwit-MacDonald A
Haematologica; 2004 Jun; 89(6):679-85. PubMed ID: 15194535
[TBL] [Abstract][Full Text] [Related]
8. Serum and urine levels of interleukin-8 in patients with non-Hodgkin's lymphoma.
Lee HL; Eom HS; Yun T; Kim HJ; Park WS; Nam BH; Moon-Woo S; Lee DH; Kong SY
Cytokine; 2008 Jul; 43(1):71-5. PubMed ID: 18502145
[TBL] [Abstract][Full Text] [Related]
9. High pretreatment interleukin-10 is an independent predictor of poor failure-free survival in patients with Hodgkin's lymphoma.
Salgami EV; Efstathiou SP; Vlachakis V; Sekara EV; Syrigos KN; Roussou PP
Haematologia (Budap); 2002; 32(4):377-87. PubMed ID: 12803112
[TBL] [Abstract][Full Text] [Related]
10. Elevated serum levels of CC thymus and activation-related chemokine (TARC) in primary Hodgkin's disease: potential for a prognostic factor.
Weihrauch MR; Manzke O; Beyer M; Haverkamp H; Diehl V; Bohlen H; Wolf J; Schultze JL
Cancer Res; 2005 Jul; 65(13):5516-9. PubMed ID: 15994922
[TBL] [Abstract][Full Text] [Related]
11. Clinical correlates of elevated serum levels of interleukin 6 in patients with untreated Hodgkin's disease.
Seymour JF; Talpaz M; Hagemeister FB; Cabanillas F; Kurzrock R
Am J Med; 1997 Jan; 102(1):21-8. PubMed ID: 9209197
[TBL] [Abstract][Full Text] [Related]
12. Serum levels of sCD137 (4-1BB) ligand are prognostic factors for progression in acute myeloid leukemia but not in non-Hodgkin's lymphoma.
Hentschel N; Krusch M; Kiener PA; Kolb HJ; Salih HR; Schmetzer HM
Eur J Haematol; 2006 Aug; 77(2):91-101. PubMed ID: 16800841
[TBL] [Abstract][Full Text] [Related]
13. Cytokine deregulation in hematological malignancies: clinical and biological implications.
Kurzrock R
Clin Cancer Res; 1997 Dec; 3(12 Pt 2):2581-4. PubMed ID: 9815659
[TBL] [Abstract][Full Text] [Related]
14. Pre-treatment serum levels of interleukin-10, interleukin-12 and their ratio predict response to therapy and probability of event-free and overall survival in childhood soft tissue sarcomas, Hodgkin's lymphomas and acute lymphoblastic leukemias.
Bien E; Balcerska A; Adamkiewicz-Drozynska E; Rapala M; Krawczyk M; Stepinski J
Clin Biochem; 2009 Jul; 42(10-11):1144-57. PubMed ID: 19376105
[TBL] [Abstract][Full Text] [Related]
15. [Immunohistochemical in situ demonstration of cytokines in Hodgkin and non-Hodgkin lymphoma].
Müller H; Takeshita M; Krause J; Schuster K; Kikuchi M; Stutte HJ
Verh Dtsch Ges Pathol; 1992; 76():164-8. PubMed ID: 1283251
[TBL] [Abstract][Full Text] [Related]
16. Limited usefulness of CA125 measurement in the management of Hodgkin's and non-Hodgkin's lymphoma.
Bonnet C; Beguin Y; Fassotte MF; Seidel L; Luyckx F; Fillet G
Eur J Haematol; 2007 May; 78(5):399-404. PubMed ID: 17419741
[TBL] [Abstract][Full Text] [Related]
17. [Measurement of five cytokines in the serum of malignant lymphoma patients].
Zhu H; Wang Y; Han X
Zhonghua Xue Ye Xue Za Zhi; 1998 Feb; 19(2):85-8. PubMed ID: 10921109
[TBL] [Abstract][Full Text] [Related]
18. [Plasma interleukin-6 and interleukin-10 levels in different subtypes of lymphoma and their clinical significance].
Wang X; Zhao HR; Gu X; Liu P; Bikmituofu H
Nan Fang Yi Ke Da Xue Xue Bao; 2011 Aug; 31(8):1360-4. PubMed ID: 21868324
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of TNF alpha and its p55 soluble receptor in malignant lymphomas.
Warzocha K; Salles G; Bienvenu J; Barbier Y; Bastion Y; Doche C; Rieux C; Coiffier B
Leukemia; 1997 Apr; 11 Suppl 3():441-3. PubMed ID: 9209418
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the prognostic meaning of C-reactive protein (CRP) in children and adolescents with classical Hodgkin's lymphoma (HL).
Haase R; Vilser C; Mauz-Körholz C; Hasenclever D; Kluge R; Ruschke K; Borkhardt A; Seeger K; Lehrnbecher T; Kulozik A; Rößler J; Burdach S; Jürgens H; Körholz D
Klin Padiatr; 2012 Oct; 224(6):377-81. PubMed ID: 23047832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
